Log in with your email address username.

×

[Comment] Gene therapy for age-related macular degeneration

Age-related macular degeneration is the most common cause of untreatable blindness in the world, and its prevalence is increasing.1 Current therapies for neovascular age-related macular degeneration aim to prevent growth of the abnormal retinal blood vessels that could leak and cause rapid visual loss in the later stages of the disease. This growth inhibition is achieved by regular injections into the eye of molecules that block the activity of vascular-endothelial growth factor (VEGF).2 These drugs are expensive, and the requirement for regular and indefinite intraocular injections puts a substantial strain on health-care resources.

email